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Note from the Editor T his is the first issue of Menopause International, which was previously the Journal of the British Menopause Society. The geographical spread of authors in this issue, covering the USA, Canada, Sweden, Spain, Italy and Australia, reflects the international nature of the journal. The presentation and layout of the journal have changed dramatically to improve readability. Since Menopause International adheres to the principles of ethical publishing, the journal is now a member of the Committee on Publication Ethics (COPE).
The theme of this first issue is common health problems affecting menopausal women and therapeutic advances. The issue starts with an editorial by Anna Glasier, on pregnancy after age 45. Throughout the Western world pregnancies in older women are increasing. In this age group, fertility has already declined and pregnancy is more likely to fail, or to be complicated by pre-eclampsia and gestational diabetes. She concludes that late childbearing should not be encouraged, but it is very unlikely that the trend can be discouraged.
Thyroid dysfunction affects 10-15% of women. Untreated disease leads to vague and insidious symptoms and exacerbates the risk of osteoporosis and cardiovascular disease. Elizabeth Pearce suggests that, while screening for thyroid dysfunction in asymptomatic individuals is controversial, aggressive case-finding should be pursued, especially in older women.
Menstrual blood loss increases with age and at least one-third of women will complain of heavy blood loss at some time during their lives. The problem is compounded by the erratic periods women can have in the perimenopause. Kirsten Duckitt discusses the evidence on medical management; intrauterine progestogens have significantly changed our practice.
The symptoms of acute myocardial infarction and acute coronary syndromes differ between the sexes. Women are less likely to experience chest pain. Normal or non-obstructive coronary disease at angiography is more common in women. Karin Schenck-Gustafsson concludes that diagnostic tests have to be specifically tailored to women.
High plasma concentrations of homocysteine have been associated with cardiovascular disease. Marco Gambacciani and Paolo Mannella review the evidence in menopausal women. They conclude that while measuring homocysteine levels is relatively simple, further evidence is awaited. Also, the benefits of reducing homocysteine levels with vitamin supplements are highly debated.
Currently four selective estrogen receptor modulators (SERMs) are licensed for clinical use: tamoxifen, toremifene, clomifene and raloxifene. An ideal SERM would reduce the risk of breast cancer and cardiovascular disease and prevent osteoporosis without stimulating the endometrium, inducing hot flushes, or increasing risk of venous thromboembolism. Santiago Palacios examines the evidence regarding new-generation SERMS, such as bazedoxifene, arzoxifene, lasofoxifene and ospemifene.
The efficacy of calcium and vitamin D in osteoporosis is controversial. Richard Prince finds that, with certain caveats, calcium with vitamin D therapy in the older postmenopausal woman can lead to useful reductions in fracture rates and falls, especially in populations with reduced exposure to sunlight. However, estrogen, SERMS and bisphosphonates are more efficacious in preventing fracture when they are given in addition to calcium and vitamin D.
Prolapse is extremely common and the recurrence rate of most of the traditional surgical procedures is high. Alex Slack and Simon Jackson discuss the use of grafts and minimally invasive surgical techniques. These procedures may improve the outcome of surgery for prolapse. However, long-term data from randomized trials are required.
The issue is concluded with a Consensus Statement from the Council of the British Menopause Society on the management of premature ovarian failure, the literature review by John McGarry and the news section by Simon Brown.
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